Orrön Energy AB (“Orrön Energy”) is pleased to announce the composition of the Nomination Committee for the 2027 Annual General Meeting (“AGM”) to be held on 14 April 2027.

The Nomination Committee has been formed with the following members:

  • Aksel Azrac (Nemesia S.à.r.l.)
  • Richard Ollerhead (JNE Partners LLP)
  • Sussi Kvart (Handelsbanken Fonder AB)

At the Nomination Committee’s first meeting, Aksel Azrac was elected as Chair of the Nomination Committee.

The Nomination Committee shall make recommendations to the 2027 AGM regarding:

  • Election of the Chair of the 2027 AGM
  • Remuneration of the members of the Board of Directors, distinguishing between the Chair and other members, and remuneration for Board Committee work
  • Election of members of the Board of Directors, including number of members
  • Election of the Chair of the Board of Directors
  • Remuneration of the auditor
  • Election of the auditor
  • Nomination Committee Process for the 2028 AGM, if any amendments are proposed to the Process for the 2027 AGM

Shareholders who wish to present a motion to the Nomination Committee regarding the above-mentioned matters, should contact the Chair of the Nomination Committee, Aksel Azrac, at nomcom@orron.com no later than 31 December 2026.

For further information, please contact:

Robert Eriksson
Corporate Affairs and Investor Relations
Tel: +46 701 11 26 15
robert.eriksson@orron.com

Jenny Sandström
Communications Lead
Tel: +41 79 431 63 68
jenny.sandstrom@orron.com

Orrön Energy is an independent, publicly listed (Nasdaq Stockholm: “ORRON”) renewable energy and infrastructure company within the Lundin Group of Companies. The Company combines exposure to Nordic power markets and long-term cash flows from renewable power generation, with significant upside from a European development business comprising large-scale solar, battery, and data centre projects. With financial capacity to fund further growth and acquisitions, and backed by a major shareholder, management team and Board with a proven track record of investing into, leading and growing highly successful businesses, Orrön Energy is well positioned to create shareholder value through the energy transition.

Forward-looking statements
Statements in this press release relating to any future status or circumstances, including statements regarding future performance, growth and other trend projections, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “seek”, “will”, “would” or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that could occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to several factors, many of which are outside the company’s control. Any forward-looking statements in this press release speak only as of the date on which the statements are made and the company has no obligation (and undertakes no obligation) to update or revise any of them, whether as a result of new information, future events or otherwise.

Attachment

Positive weekly earnings and hours worked growth trends continue

ROCHESTER, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) — According to the Paychex Small Business Employment Watch, which reports on employment levels in U.S. small businesses with fewer than 50 employees, the pace of job growth increased 0.02 percentage points to 99.15 in September. The jobs index remained broadly in line with the 2026 year-to-date average of 99.19. Hourly earnings growth remained below three percent in September (2.78%), extending a more than two-year trend of moderating wage growth. At the same time, weekly earnings and hours worked growth remained positive, indicating businesses continue to meet demand through existing workforce capacity.

“The small business labor market continues to demonstrate remarkable stability,” said John Gibson, Paychex president and CEO. “Our data shows businesses are largely maintaining staffing levels. The pace of employment growth across our overall client base improved slightly in September, with stronger growth among businesses with more than 50 employees. Sustained increases in weekly earnings and hours worked growth demonstrate that businesses continue to meet operational needs without increasing hiring. With hourly earnings growth remaining below three percent for more than two years, labor cost pressures have become more manageable. These trends point to a labor market that remains fundamentally solid.”

Jobs Index and Wage Data Highlights

  • Hourly earnings growth (2.78%) moderated slightly in September as one-month annualized growth (2.41%) slowed to its lowest level in nearly six years (October 2020: 2.40%).
  • Weekly earnings growth increased to 3.07% in September, marking the ninth consecutive month of growth.
  • Weekly hours worked growth (0.21%) was positive for the seventh consecutive month in September.
  • The Midwest remained the top region for small business employment growth with a 99.62 jobs index in September.
  • Arizona (100.59) led states for small business job growth in September and has reported an index level above 100 for the last five months. Phoenix (101.31) led U.S. metros for job growth in September.
  • Education and Health Services (99.79) remained the top sector for small business job growth in September and has ranked among the top two sectors every month since February 2023.


About the Paychex Small Business Employment Watch

Since 2014, the Paychex Small Business Employment Watch has been a trusted source of employment trends for U.S. small businesses with fewer than 50 employees. The Employment Watch website offers interactive charts and historical data across the report’s two key components – the jobs index and wage data – as well as the methodology for both analyses. Visit the Bloomberg Terminals or subscribe to receive monthly alerts with the latest data.

paychex-small-business-employment-watch-september-2026

*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.

About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 840,000 customers and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI engine embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.

Media Contacts
Tracy Volkmann
Paychex, Inc.
Manager, Public Relations
(585) 387-6705
tvolkmann@paychex.com

Erin McAward
ICR, Inc.
Account Director
paychexpr@icrinc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3545f218-10d1-412e-80d3-9e3960084691

Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients

ACCLARENT AERA® Eustachian Tube Balloon Dilation System

ACCLARENT AERA® Eustachian Tube Balloon Dilation System
ACCLARENT AERA® Eustachian Tube Balloon Dilation System

PRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-world clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients eight or older.

The milestone represents one-third of the registry’s planned enrollment of 300 patients and reflects the continued collaboration of participating investigators, research coordinators and clinical sites across the United States. Launched in July 2025, the registry is designed to generate real-world evidence regarding the use of AERA in children with obstructive Eustachian tube dysfunction, or ETD.

“Reaching the 100-patient milestone reflects meaningful progress in building real-world evidence in pediatric Eustachian tube dysfunction and its treatment,” said Christopher Schutt, M.D., vice president, Operations & Excellence, Office of the Chief Medical Officer, Integra LifeSciences. “We are grateful to the research teams and families whose participation is making this work possible. We are hopeful their contributions will help inform future clinical decision-making and advance understanding of care for children with ETD.”

ETD occurs when the Eustachian tube does not properly regulate pressure or drain fluid from the middle ear. The condition may contribute to symptoms including ear pressure or fullness, discomfort, hearing difficulties, and recurrent ear infections. Eustachian tube balloon dilation is a treatment option for appropriate patients with ETD.

“This milestone reinforces our commitment to the ear, nose, and throat (“ENT”) market and to advancing the evidence base supporting innovative treatment options for patients with Eustachian tube dysfunction,” said Harvinder Singh, executive vice president and president, Specialty Surgery, Integra LifeSciences. “We believe continued investment in clinical evidence generation is essential to supporting physicians, informing care decisions and strengthening our leadership position in ENT.”

AERA received FDA clearance for its pediatric indication in December 2023, becoming the first and only Eustachian Tube Balloon Dilation System indicated for pediatric patients ages eight and older.1

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

About ACCLARENT AERA® Eustachian Tube Balloon Dilation System

The ACCLARENT AERA Eustachian Tube Balloon Dilation System is intended to dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in patients ages 18 and older. For patients ages 8-17 years, the ACCLARENT AERA Eustachian Tube Balloon Dilation System, alone or in combination with adjunctive procedures, is intended to treat patients with objective signs of persistent obstructive Eustachian tube dysfunction from inflammatory pathology, resulting in chronic otitis media with effusion and are refractory to at least one surgical intervention for persistent obstructive Eustachian tube dysfunction.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. Forward-looking statements that may be discussed include, but are not limited to, the potential clinical application and efficacy of the AERA Eustachian Tube Balloon Dilation System in pediatric patients, the number of patients expected to be involved in the AERA Pediatric Registry and the anticipated utility of data collected from the AERA Pediatric Registry. There can be no assurance that the AERA Pediatric Registry will be able to meet the enrollment and observation objectives described herein or that any potential clinical applications and benefits will be observed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra LifeSciences’s business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra LifeScience’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra LifeSciences undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

______________
1
U.S. Food and Drug Administration. ACCLARENT AERA Eustachian Tube Dilation System (K230742). Dec. 13, 2023. Website: FDA 510(k) Clearance Database – ACCLARENT AERA K230742 [accessdata.fda.gov]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4ef670f8-0782-4879-8f56-55f9ef15506a

CompuFlo Builds Momentum as Physician Adoption, Reimbursement Access, Commercial Coverage and Clinical Evidence Expand

ROSELAND, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today highlighted continued progress in building a structured and scalable growth platform for its CompuFlo® medical business.

“We are building CompuFlo into a scalable medical business, and the early results are demonstrating the potential of that strategy,” said Eric Hines, Chief Executive Officer of Milestone Scientific. “Our growth in medical segment revenue reflects increasing market activity, while the expansion of our Advisor Program, reimbursement access, commercial organization and clinical footprint is creating the infrastructure to support much broader adoption. We are focused on converting physician experience into repeat utilization, expanding our presence in reimbursed markets and building the recurring disposable revenue model that can support sustained growth.”

Milestone has implemented a coordinated strategy centered on physician adoption, reimbursement, dedicated commercial execution, clinical support, market development and evidence generation. Together, these initiatives are designed to increase utilization, drive recurring disposable revenue and establish a repeatable model for geographic expansion.

Advisor Program Expanding Physician Experience and Adoption

A central element of the Company’s strategy is the CompuFlo Advisor Program, designed to accelerate hands-on physician experience, encourage repeat utilization, generate real-world reimbursement experience and identify physician champions who can support broader adoption.

Through September 2026, the Advisor Program generated over 180 epidural procedure feedback submissions across Medicare, commercial and other payer categories. This builds on an earlier evaluation involving 145 epidural procedures across seven U.S. states, where 99.3% of respondents reported CompuFlo was easy to use and all participating physicians indicated they would recommend the technology to colleagues.

The Company believes this growing base of physician experience can provide an important foundation for developing reference accounts, physician advocates and repeat utilization as commercial coverage expands.

Reimbursement Creates a Framework for Commercial Expansion

Milestone has also established an important reimbursement foundation for CompuFlo-guided procedures.

Healthcare providers currently have access to Medicare payment of approximately $325 per procedure under CPT® Category III code 0777T in the Novitas and First Coast jurisdictions. The Company is concentrating its commercial resources within these reimbursed markets while expanding activity within Palmetto and pursuing additional Medicare and commercial payer opportunities. Milestone has partnered with Avania Medical LLC for reimbursement and market-access support to help providers navigate reimbursement and support broader adoption.

The Company’s strategy is to establish utilization in markets where reimbursement is available, develop reference accounts and physician champions, and use those experiences to support expansion into additional jurisdictions.

Expanded Commercial Infrastructure Extends Market Coverage

Milestone has significantly expanded its commercial infrastructure to extend coverage. The organization now includes three dedicated medical sales professionals, approximately 15 sales consultants, three distribution partners, clinical and reimbursement support, physician advisors and key opinion leaders, with additional resources being added to expand coverage across other MAC jurisdictions.

This broader field organization is designed to reach key care settings including interventional pain practices, multisite physician groups, ambulatory surgery centers, hospitals and academic medical centers. The Company is pursuing a focused commercial model intended to combine direct sales resources, distribution partners, physician education, reimbursement support and clinical expertise.

“We are building commercial infrastructure around utilization rather than simply device placement,” said Mr. Hines. “The objective is to support physicians through the adoption process, help establish successful reference accounts and create the infrastructure needed to replicate that success across additional markets.”

Clinical Evidence Supporting Broader Utilization

Clinical validation continues in parallel with commercial expansion. CompuFlo has been evaluated or utilized at more than 40 universities, academic medical centers and teaching hospitals worldwide.

A recent 79-patient peer-reviewed University of Texas Medical Branch study associated CompuFlo-guided epidural access during spinal cord stimulator implantation with approximately a 91% reduction in the adjusted odds of composite complications compared with conventional loss-of-resistance techniques.

Additional research is underway, including a University of Minnesota study evaluating CathCheck® against epidurography for confirmation of epidural catheter placement, targeting approximately 50 participants. The Company believes continued clinical research can support broader utilization across pain management, neuromodulation, obstetric and other epidural procedures.

Physician Education and Market Development

The Company is also increasing physician awareness and market recognition through participation in leading pain and neuromodulation meetings, including NANS, ASPN, FSIPP, ISPN and other regional and international conferences, together with webinars, physician education and direct engagement with key opinion leaders.

These activities are intended to complement the Company’s commercial and clinical initiatives by increasing physician familiarity with CompuFlo and creating additional opportunities for hands-on evaluation and adoption.

International Market Development Expands Growth Opportunities

Internationally, Milestone is advancing market-development activities in Italy, Chile and Qatar, while evaluating additional opportunities across Europe, Latin America, the Middle East and Asia. The Company is pursuing international expansion through local distributors, physician champions, clinical education and targeted conference participation.

Milestone intends to apply the same general commercialization framework internationally: identify appropriate reimbursement and market-access pathways, establish physician experience and reference accounts, support clinical education and develop local commercial capabilities.

Positioned to Scale Utilization and Recurring Revenue

Mr. Hines concluded, “We have moved beyond establishing the building blocks of the CompuFlo medical business and are now focused on scaling the platform we have built. Physician adoption is expanding, reimbursement pathways are developing, our commercial organization is materially broader, and a growing body of clinical experience and evidence is supporting the technology.

“Our objective is to increase utilization, convert physician experience into recurring procedure volume and disposable revenue, expand our presence in reimbursed U.S. markets, and replicate that model across additional U.S. and international markets. As we continue to build the clinical and utilization evidence around CompuFlo, we are also working toward the longer-term opportunity to support a future transition of CPT 0777T from Category III to Category I.

“We believe the opportunity ahead is not simply to place more devices, but to establish CompuFlo as a repeat-use technology embedded in everyday clinical practice. The infrastructure we are putting in place today is designed to support that objective and create a scalable medical business with increasing recurring revenue potential.”

About Milestone Scientific Inc.

Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Any potential Category I designation is determined solely by the American Medical Association and is not guaranteed. Providers remain responsible for compliance with all applicable billing, coding, and regulatory requirements. Forward-looking case submission expectations, reimbursement targets, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity, and are subject to change based on clinical scheduling, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted reimbursement levels, or projected revenue levels will be achieved. This release also contains forward-looking statements regarding the development, capabilities, adoption, timing and expected benefits of Milo and Milestone’s broader artificial intelligence strategy, and the anticipated impact of the Company’s distribution agreement with Red One Medical, which does not guarantee contract awards, product evaluations, purchase orders or adoption by any federal agency or healthcare facility.

Contact:

HAYDEN IR:

James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.

The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better recognize and manage diseases that have historically been overlooked or undertreated.

“These 11 abstracts reflect the rapidly evolving understanding of Demodex blepharitis and ocular rosacea—two significant diseases that eye care professionals encounter every day. The findings deepen our understanding of each disease and the impact they can have on patients,” said Elizabeth Yeu, M.D., Chief Medical Officer of Tarsus.

Accepted abstracts include:

Real-World Longitudinal Study of Patients with Demodex Blepharitis and Soft Contact Lens Wear in the United States: Interim Data Analysis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: Anaheim Convention Center (ACC), Exhibit Hall
Presenter: Keith Wan, O.D.

Efficacy of Lotilaner 0.25% and Tea Tree Oil in Demodex Blepharitis: A Systematic Review and Meta-analysis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Ian B. Gaddie, O.D.

Retrospective Chart Review of Demodex Blepharitis Prevalence Among Patients with Chalazia and/or Hordeola (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Andrew McLeod, O.D.

Prevalence of Ocular Rosacea in U.S. Eye Care Settings: A Multicenter Retrospective Chart Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Mile Brujic, O.D.

Assessment of Dry Eye Questionnaires for Demodex Blepharitis: Evidence from a Targeted Literature Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Walt Whitley, O.D.

Real-World Longitudinal Study of Patients with Demodex Blepharitis in the United States: 9-Month Follow-up Findings (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Vanesa Flores, O.D.

Real-World Clinician Re-treatment Practices and Decision Drivers with Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Cecelia Koetting, O.D.

Real-World Patient-Reported Satisfaction and Factors Associated with Perceived Benefit of Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Jessilin Quint, O.D.

Associations Between Demodex Infestation and Meibomian Gland Structure and Function: A Systematic Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Bridgitte Shen Lee, O.D.

Ocular Bacterial and Fungal Co-infestation in Demodex Infestation: A Systematic Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Pamela Theriot, O.D.

Assessment of Tea Tree-Based Management in Demodex Blepharitis: A Real-World Longitudinal Study (Paper)
Date: Friday, October 2, 2026, 4:00 – 4:15PM Pacific Daylight Time
Location: ACC, Room 255 C
Presenter: Selina McGee, O.D.

About Demodex Blepharitis
Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasites found on humans, and accounts for over two-thirds of all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex mite infestation, and that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact on patients’ daily lives.

About XDEMVY®
XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

XDEMVY Indication and Important Safety Information

Indications and Usage
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

Important Safety Information
Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician’s advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information please see Full Prescribing Information available at: www.xdemvy.com.

About Ocular Rosacea
Ocular rosacea is a prevalent, undertreated inflammatory disease affecting the eyes, eyelids and surrounding tissue. The condition may be associated with redness of the eyes and eyelids, prominent blood vessels, irritation and other ocular symptoms. Ocular rosacea is estimated to affect 15–18 million people in the United States, and there are currently no FDA-approved therapies specifically indicated for the disease.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the timing, content, location, and presenters of scientific abstracts at an upcoming medical conference, our ability to continue to educate the market and generate data about Demodex blepharitis, the potential market size of Demodex blepharitis globally, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2025 filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com 

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com 

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalation (Part A) followed by dose expansion (Part B), is intended to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of PRP.

Several workstreams are advancing in parallel to support study start:

  • Manufacturing: GMP manufacture of finished drug product is underway. A small-scale technology transfer run has been completed. Two scale-up runs are scheduled this month, with an engineering run planned for late October. Raw drug substance supply for the PRP formulation is secured after recent audit and vendor qualification processes were successfully completed.
  • Bio-analytics: PK method validation has commenced. Development of an anti-drug antibody assay is underway, and in-use stability testing of the finished PRP formulation is scheduled.
  • Regulatory and ethics: Supporting documentation for Human Research Ethics Committee (HREC) submission is in preparation, including the Investigator’s Brochure (IB), a briefing document drawn from the IB, and the clinical trial protocol. Documents will be provided to investigators at Australian trial sites for feasibility assessment ahead of the planned HREC submission in November 2026.

PRP will be administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. Treatment may continue until a withdrawal criterion is met.

Compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC)

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

  • Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001).
  • Marked reduction in metastatic burden in the liver and peritoneum.
  • Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers.
  • Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
  • Median overall survival extension of more than 2.5-fold in treated animals compared with controls.

Results were built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile and no severe treatment-related adverse events.

Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd

The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc’s Phase 1b, FIH clinical study for PRP. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving with the goal of advancing PRP efficiently from FIH into Proof-of-Concept and, as data supports, later-phase development. Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe. With more than 30 years of experience leading early phase clinical trials, they leverage the unique advantages of the Australian market, including rapid ethics approval, and up to 43.5% off with the Australian R&D tax rebate, to provide biotech companies with an accelerated pathway to clinical success.

Contract and Development Manufacturing Organization (CDMO) for GMP manufacture of PRP

The Spanish based CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products. Management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study.

Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b FIH Study

Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b FIH study.

Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén & Granada, Spain

A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc to UJA’s research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.”

FINANCIAL HIGHLIGHTS

Proceeds raised

In the 2025-26 financial year totaled $7.5 million, gross proceeds.

Closed an underwritten public offering

1,000,000 shares at $4.00 per share, raising gross proceeds of $4.0 million. Propanc’s common stock began trading on the Nasdaq Capital Market on August 15.

Entered into a private placement agreement for up to $100 million to accelerate clinical development

Received an initial $1,000,000 investment upon issuance of 100 shares of Series C, Convertible Preferred Stock. As of June 30, a further $3,000,000 investment was received upon exercise of 100 shares of Series C, Convertible Preferred Stock.

Commenced a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock

The Company completed the first tranche of $500,000 within the first 30 days since of commencing its share repurchase program.

Year-end Financial Summary (Quarter Ended June 30, 2026)

  • Total assets: $12.78 million
  • Total liabilities reduced by $2.20 million
  • Convertible notes reduced to $0 (from $538,000)
  • Net cash from financing activities: $6.46 million
  • Quarter-end cash: $832,006
  • A further $2.0 million from the Series C facility received (post June 30)

The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.

Management Commentary

“The Propanc Executive team are delighted with advancements made in the past financial year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “The Company is poised to capitalize on the foundation set in the next financial year with the advancement of PRP to a Phase 1b FIH study in up to 50 advanced cancer patients with solid tumors such as pancreatic, ovarian and refractory prostate cancers. Recent clinical advancements observed by companies such as Revolution Medicines and Erasca through KRAS inhibitors for pancreatic cancer are groundbreaking and tremendously exciting, but there is more work to be done to eliminate recurrence and metastasis in patients suffering from this killer disease. PRP is a potential breakthrough therapy that modulates the tumor micro-environment by targeting the EMT (epithelial-mesenchymal transition) process, which drives metastasis, invasion and recurrence from CSCs (cancer stem cells) which often lie dormant, post treatment, causing the cancer to return and spread. By eliminating this threat, not only can PRP improve survival, but is also non-toxic to healthy cells, meaning that patients could have a better quality of life, as well as enhance more durable response rates in combination with other treatments such as chemotherapy, checkpoint inhibitors, or KRAS inhibitors. We look forward to executing our scientific and clinical research activities in the 2026-2027 financial year.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:

irteam@propanc.com


Clinical Research Activity for PRP   Timeline
CTA   April 2025 – September 2026
     
Phase Ib Clinical Study Protocol    
Investigator’s Brochure    
CTA Compilation   October 2026 – November 2026
CTA Submission   November 2026
CTA Approval   February 2027
CTA Review   January 2027 – February 2027
Contract Research Organization and Contracts   February 2027 – March 2027
Analytical Laboratory Selection and Contracts    
Trial Site Selection and Contracts    
Preparation of Logistics   February 2027 – March 2027
Trial Site Initiation Visits    
First Patient/First Visit   April 2027
     

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
 
             
    June 30, 2026     June 30, 2025  
             
ASSETS                
                 
CURRENT ASSETS:                
Cash   $ 832,006     $ 12,088  
GST tax receivable     13,694       5,302  
Prepaid expenses – current portion     7,661,967       8,334,046  
Other current assets     34,923       1,380  
                 
TOTAL CURRENT ASSETS     8,542,590       8,352,816  
                 
Deferred offering costs     –       291,773  
Prepaid expenses – long-term portion     4,190,543       10,925,835  
Security deposit – related party     2,074       1,971  
Operating lease right-of-use assets, net – related party     40,790       59,413  
Property and equipment, net     3,915       –  
                 
TOTAL ASSETS   $ 12,779,912     $ 19,631,808  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
CURRENT LIABILITIES:                
Accounts payable   $ 1,131,429     $ 1,249,596  
Accrued expenses and other payables     855,350       1,486,550  
Accrued interest     128,318       190,795  
Loans payable     –       65,280  
Loans payable – related parties, net of discount     460,809       415,329  
                 
Notes payable, net of discount     –       543,312  
Convertible notes, net of discounts and including put premiums     –       537,921  
Operating lease liability – related party, current portion     24,489       17,664  
Embedded conversion option liabilities     –       403,892  
Employee benefit liability     754,038       667,901  
                 
TOTAL CURRENT LIABILITIES     3,354,433       5,578,240  
                 
NON-CURRENT LIABILITIES:                
Loan payable – long-term – related party, net of discount     –       105,627  
Operating lease liability – long-term portion – related party     23,818       41,749  
                 
TOTAL NON-CURRENT LIABILITIES     23,818       147,376  
                 
TOTAL LIABILITIES   $ 3,378,251     $ 5,725,616  
                 
Commitments and Contingencies (See Note 9)                
                 
STOCKHOLDERS’ EQUITY:                
Preferred stock, 1,500,005 shares authorized, $0.01 par value:                
Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of June 30, 2026 and 2025   $ –     $ –  
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of June 30, 2026 and 2025     –       –  
Series C preferred stock, $0.01 par value, $10,000 stated value; 5 shares authorized; 9,900 shares designated and authorized, 200 (liquidation value of $2,000,000) shares and none issued and outstanding at June 30, 2026 and 2025, respectively     2       –  
                 
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 3,310,827 and 464,471 shares issued and outstanding as of June 30, 2026 and 2025, respectively     3,310       464  
Common stock issuable (487,939 and 310 shares as of June 30, 2026 and 2025, respectively)     487       –  
Additional paid-in capital     152,752,314       138,254,808  
Accumulated other comprehensive income     1,176,255       1,318,917  
Accumulated deficit     (144,484,230 )     (125,621,520 )
Treasury stock ($0.001 share)     (46,477 )     (46,477 )
                 
TOTAL STOCKHOLDERS’ EQUITY     9,401,661       13,906,192  
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 12,779,912     $ 19,631,808  
                 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
             
    For the years ended June 30,  
    2026     2025  
             
REVENUE                
Revenue   $ –     $ –  
                 
OPERATING EXPENSES                
Administration expenses     670,607       108,950  
Compensation and related taxes     2,275,937       23,296,390  
Professional and consulting expenses     14,572,616       33,622,510  
Occupancy expenses – related party     40,932       26,560  
Research and development     625,477       223,721  
TOTAL OPERATING EXPENSES     18,185,569       57,278,131  
                 
LOSS FROM OPERATIONS     (18,185,569 )     (57,278,131 )
                 
OTHER INCOME (EXPENSE)                
Interest expense     (430,539 )     (563,757 )
Interest income     161       9  
Derivative expense     –       (333,596 )
Change in fair value of derivative liabilities     13,709       212,450  
Change in fair value of warrant liability     (99,695 )     –  
Other expense     (6,000 )     –  
Settlement expense     (320,000 )     –  
Gain (loss) on extinguishment of debt, net     133,071       (871,032 )
Foreign currency transaction gain (loss)     32,152       (89,243 )
TOTAL OTHER INCOME (EXPENSE), NET     (677,141 )     (1,645,169 )
                 
LOSS BEFORE TAXES     (18,862,710 )     (58,923,300 )
                 
Tax benefit     –       –  
                 
NET LOSS   $ (18,862,710 )   $ (58,923,300 )
                 
Deemed Dividend     (932,246 )     –  
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS   $ (19,794,956 )   $ (58,923,300 )
                 
BASIC AND DILUTED NET LOSS PER SHARE   $ (17.62 )   $ (371.22 )
                 
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING     1,123,709       158,727  
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS   $ (19,794,956 )   $ (58,923,300 )
                 
OTHER COMPREHENSIVE INCOME (LOSS)                
Unrealized foreign currency translation gain (loss)     (142,662 )     49,336  
                 
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)     (142,662 )     49,336  
                 
TOTAL COMPREHENSIVE LOSS   $ (19,937,618 )   $ (58,873,964 )

Vancouver, BC, Sept. 29, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in humanoid robotics and embodied artificial intelligence (“AI”), is pleased to highlight recent corporate and commercial developments announced by MBody AI Ltd. (“MBody AI”) (Nasdaq: MBAI), a portfolio company in which Humanoid Global holds a minority equity interest.

MBody AI announced that, on August 26, 2026, Check-Cap Ltd. completed its business combination with MBody AI Corp. Under the transaction, MBody AI Corp. became a wholly owned subsidiary of Check-Cap, and Check-Cap shareholders approved a corporate name change to MBody AI Ltd. The combined company continues to trade on Nasdaq under the symbol MBAI.

MBody AI further announced the closing, on August 27, 2026, of an underwritten public offering of 1,538,462 ordinary shares at a public offering price of $6.50 per share, for gross proceeds of approximately 10.0 million before underwriting discounts, commissions and offering expenses. The underwriter was granted a 30-day option to purchase up to an additional 230,769 ordinary shares at the public offering price, less applicable underwriting discounts and commissions.

Separately, on September 9, 2026, MBody AI announced that it had completed a proof-of-concept deployment of autonomous robotic systems at Mohegan Sun in Uncasville, Connecticut. According to MBody AI, the systems continued operating following the conclusion of the pilot and transitioned to a paid commercial agreement with Mohegan Sun.

MBody AI has stated that its robots operated across Mohegan Sun’s gaming floor and conference centre, including full day and evening shifts, and performed repetitive and time-sensitive tasks. MBody AI further stated that the deployment is managed through its “MBody AI Orchestrator,” a hardware-agnostic platform intended to coordinate robot fleets across sites and use cases.

According to MBody AI, Mohegan Sun has indicated its intention to expand the deployment under a multi-year subscription arrangement later in 2026. Any such expansion remains subject to negotiation and execution of definitive agreements between MBody AI and Mohegan Sun.

“The completion of MBody AI’s business combination and financing represents an important transition for the company as it advances its embodied-AI and autonomous-robotics strategy as a Nasdaq-listed issuer,” said Sunny Ray, Chief Executive Officer of Humanoid Global. “We believe the paid commercial deployment at Mohegan Sun provides an additional operating example of MBody AI’s approach to converting robotics deployments into recurring commercial relationships. Humanoid Global continues to monitor and support the progress of its portfolio companies while maintaining disciplined minority-investment positions.”

Humanoid Global does not control or operate MBody AI and is not a party to MBody AI’s arrangement with Mohegan Sun, its business combination with Check-Cap, or its public offering. The Company holds securities of MBody AI and, subject to applicable securities laws, may acquire or dispose of such securities from time to time.

Humanoid Global invests in companies supporting the commercial adoption of robotics, automation and embodied AI across the global economy.

-##-

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp.  (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more:
https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer

finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the anticipated expansion, timing, scope, terms and commercial benefits of MBody AI’s deployment at Mohegan Sun; the potential negotiation and execution of a multi-year subscription agreement or other expansion arrangement between MBody AI and Mohegan Sun; the continuation, renewal or extension of MBody AI’s commercial engagement at Mohegan Sun; MBody AI’s ability to convert proof-of-concept or pilot deployments into commercial operations; MBody AI’s ability to deploy, operate, scale and commercialize its autonomous robotics systems and fleet-orchestration platform; the anticipated use of proceeds from MBody AI’s public offering; and the Company’s expectations regarding its investment in MBody AI.

Forward-looking information is based on assumptions that MBody AI’s commercial engagement with Mohegan Sun will continue substantially as anticipated; the parties will be able to negotiate and execute any proposed expansion agreement on acceptable terms; MBody AI will have sufficient capital, personnel, technology, equipment, commercial partners and other resources to support its current and future deployments; MBody AI will be able to maintain its Nasdaq listing and comply with applicable regulatory requirements; and market conditions and demand for autonomous robotics and embodied-AI solutions will remain supportive. These assumptions may prove to be incorrect. The Company holds a minority equity interest in MBody AI and therefore has a financial interest in MBody AI’s success and the market price of its securities; readers should consider this interest when evaluating the forward-looking information contained herein. Humanoid Global does not control or operate MBody AI, is not a party to MBody AI’s arrangement with Mohegan Sun, business combination or public offering, and has no control over the negotiation, execution, terms or performance of any MBody AI commercial agreement.

Forward-looking information is subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the risk that no expansion agreement is entered into with Mohegan Sun, or that any such agreement is entered into on different terms or at a different time than anticipated; the risk that MBody AI’s existing commercial engagement at Mohegan Sun is modified, suspended, terminated or not renewed; the risk that MBody AI’s autonomous robotic systems or orchestration platform may not perform as expected or achieve commercial acceptance; risks relating to technology performance, systems integration, safety, cybersecurity, data security, maintenance, operational reliability and customer acceptance; risks that MBody AI may require additional capital or may not be able to obtain financing on acceptable terms or at all; risks associated with MBody AI’s ability to maintain compliance with Nasdaq continued-listing requirements and other applicable regulatory requirements; customer-concentration, commercialization and competition risks; changes in applicable laws, regulations or government policies; general business, economic, financial and market conditions; and risks related to the Company’s reliance on portfolio companies in which it holds minority interests and over which it does not have control.

Additional risks are described in the Company’s public filings available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking information speaks only as of the date of this news release, and the Company undertakes no obligation to update or revise it except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information in this news release regarding MBody AI, its business combination with Check-Cap, its public offering, its autonomous robotics systems, the MBody AI Orchestrator and its deployment at Mohegan Sun has been derived from MBody AI’s public announcements and other publicly available sources. Humanoid Global has not independently verified this information. The Company is not the operating company and is not a party to the business combination, public offering, commercial arrangement, customer relationship or other operating activities described in this news release.

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset announced financial results for the fiscal year ended June 30, 2026.

Fiscal year 2026 was the Company’s first fiscal year operating under the LTC treasury strategy that commenced in August 2025. The Company deployed $100.0 million to acquire over 900,000 LTC, built the foundation of an active digital asset treasury by establishing institutional custody and professional asset management, and launched active digital asset treasury operations. Each of these elements is directed at increasing the LTC backing behind every share of LITS common stock.

Fiscal Year 2026 Operational Highlights

  • Closed a $100.0 million private placement in July 2025 and deployed the gross proceeds into LTC, establishing LTC as the Company’s primary treasury reserve asset and the largest public company holder of LTC; the Company held 832,716 LTC as of June 30, 2026, representing over 1% of LTC currently mined;
  • Led a $1.0 million strategic investment in LitVM, the first zero-knowledge Layer-2 platform bringing smart contract capability to the Litecoin network;
  • Shifted from accumulation to active capital markets operations in the second fiscal quarter, launching a covered call options program against LTC holdings and commencing repurchases of LITS common stock under a $25.0 million share repurchase program approved in October 2025;
  • Initiated pre-clinical activities for voruciclib in non-oncology indications, retaining two drug candidates for potential out-licensing or sale opportunities and future sources of non-dilutive capital.

“Fiscal 2026 was the year we built the base for a Litecoin-centered treasury program,” said Jay File, CEO & CFO of Lite Strategy. “We deployed $100 million into Litecoin with institutional custody alongside professional management through GSR Strategies, then launched a covered call program ahead of schedule that generates recurring proceeds. Those proceeds, together with the strategic utilization of our Litecoin balance, are designed to allow us the ability to monetize our discount to NAV and put more Litecoin behind every share via our ongoing buyback program. As we move into our first full year of DAT operations, we anticipate that our focus will be on accretive buybacks, expanded yield opportunities, lower operational costs and cash burn, while continuing to evaluate strategic opportunities to expand Litecoin’s utility and growth of the Litecoin ecosystem.”

Fiscal Year 2026 and Recent Financial Highlights

  • Repurchased approximately 4.4 and 6.4 million LITS shares, or 12% and 17% of shares outstanding, from the commencement of the buyback program through June 30, 2026 and September 22, 2026, respectively; halving the discount to net asset value (NAV) from the low 40% range into the low 20% range;
  • Premium proceeds generated from covered call program of approximately $930,000 from program initiation through September 22, 2026.

Cash and Liquidity
At June 30, 2026, Lite Strategy held $5.7 million in cash and cash equivalents and $34.9 million in unrestricted and collateralized digital assets, with total assets of $42.7 million and no debt. The Company had 30,407,268 shares outstanding as of September 22, 2026. Complete financial statements are available in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (Commission).

Litecoin Ecosystem Outlook
On March 17, 2026, the Commission issued the Digital Asset Interpretation, identifying LTC as a digital commodity rather than a security, with the Commodity Futures Trading Commission (CFTC) joining to confirm it will continue to regulate LTC on that basis. The Commission expanded on that guidance on August 18, 2026, proposing Regulation Crypto Assets, a tailored offering framework now open for public comment. For corporate treasuries and asset managers evaluating LTC exposure, this offers meaningful assurance that was not available a year ago.

While the CLARITY Act did not advance in the U.S. Senate, the guidance already issued by the Commission and the CFTC gives the Company a clear basis to continue executing its LTC-focused strategy under the regulatory framework and guidance currently available. The Company intends to remain focused on executing our disciplined treasury management strategy focused on long-term stockholder value creation within those requirements while monitoring legislative and regulatory developments.

“Together, these efforts introduce a comprehensive, tailored securities offering regime intended to address long-standing barriers to responsible capital formation and innovation within domestic crypto asset markets, while preserving the investor protections at the core of federal securities laws,” said Charlie Lee, Lite Strategy Board Member and creator of Litecoin.

Business Update and Strategic Focus
Looking ahead, management’s primary objective is to grow LTC holdings per share through the active management of the Company’s treasury.

We believe the opportunity underlying this strategy is significant. Institutional and corporate capital allocated to digital asset treasuries has grown rapidly over the past two years, yet that capital remains heavily concentrated in Bitcoin, leaving Litecoin as one of the longest-operating, most liquid and lowest-cost payment networks in digital assets, with a fixed, disclosed supply and a 15-year operating history; comparatively underrepresented relative to its scale, security and track record. Management believes that gap represents a durable opportunity: as regulatory clarity accelerates institutional adoption of LTC and as the network’s utility expands, demand for LTC should broaden beyond its traditional base as a payments asset. For Lite Strategy, that dynamic reinforces the core investment thesis.

As the first U.S. public company to adopt LTC as its primary treasury reserve asset and its largest public company holder, Lite Strategy offers investors a liquid, regulated, publicly traded vehicle for direct exposure to LTC’s growth, without the custody, security and operational complexity of holding the asset directly. Management believes this positioning allows the Company to compound that opportunity for stockholders as institutional awareness of, and demand for, LTC increases.

Beyond treasury management, Lite Strategy intends to invest in the growth of the Litecoin ecosystem itself. LitVM has the capacity to extend Litecoin from a payment network to a programmable one, and Lite Strategy is its lead institutional investor. Applications built on the platform broaden Litecoin’s utility, including the LTC held in the Company’s treasury. By enabling smart contracts, decentralized finance, stablecoin issuance and tokenized assets on Litecoin for the first time, LitVM should have the opportunity to meaningfully expand the network’s addressable use cases beyond payments alone, creating new sources of transaction activity and developer engagement.

Following the Digital Asset Interpretation, and with a full fiscal year of operating record with our Litecoin-centered treasury program and no outstanding debt, management intends to expand direct engagement with banking partners, analysts and allocators. Alongside sustained education in the case for LTC as an institutional asset, a broader institutional understanding of LTC supports the value of the Company’s own holdings. Management remains focused on bridging institutional capital to the Litecoin ecosystem. We believe Lite Strategy is well positioned to capture an attractive share of this opportunity as one of the only pure-play, publicly traded vehicles offering direct exposure to LTC’s growth.

About Lite Strategy
Lite Strategy Inc. (Nasdaq LITS) is a San Diego-based digital asset treasury company that holds LTC as a primary reserve asset and pursues capital markets strategies designed to generate income from those holdings while retaining long-term exposure. Formerly MEI Pharma, Inc., the Company adopted its Litecoin treasury strategy in 2025 to diversify reserves, enhance capital efficiency and align with emerging financial technologies. Lite Strategy also retains a portfolio of pharmaceutical assets that it is managing for out-licensing or sale. More information is available at litestrategy.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding LTC and its potential performance, the Company’s Litecoin treasury strategy, the share repurchase program, out-licensing or sale of pharmaceutical assets and the sufficiency of the Company’s capital resources. These statements are subject to risks and uncertainties, including volatility in the price of LTC, the regulatory treatment of digital assets, the Company’s ability to maintain compliance with Nasdaq listing standards, potential dilution from outstanding warrants and options and the other risks described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts:

Investor Relations:
Alliance Advisors IR
Adele Carey
SVP, Investor Relations
investor@litestrategy.com

Public Relations:
Impact3
Casey Wilson
Director of Public Relations
media@litestrategy.com

New agreements bring the total value of contracts signed over the past seven months to more than $3.45 billion

PITTSBURGH, Sept. 29, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) today announced that it has received more than $184 million in customer prepayments and signed over $266 million in new AI infrastructure contracts since reporting second-quarter results on August 17, 2026.

The prepayments, drawn from both newly signed agreements and existing contracts, represent capital committed ahead of delivery, underscoring surging demand and momentum as Axe Compute turns contracted commitments into revenue.

The $266 million in new contracts is incremental to previously disclosed agreements, bringing the total value of contracts signed in the past seven months to more than $3.45 billion. The new agreements have terms of up to 60 months and include Grace Blackwell 300-class hardware, accompanied by CPU nodes to run orchestration, Kubernetes, Slurm and other control functions, as well as high speed storage and dedicated network connectivity to support lightning fast inferencing and mission critical applications. These GB300 clusters support clients building AI cloud platforms and running inference, fine-tuning, and other production AI workloads.

“Customers are committing to the dedicated AI infrastructure they want with Axe Compute, and our team is executing to deliver exactly what they need to grow their businesses,” said Christopher Miglino, Chief Executive Officer of Axe Compute. “Demand is clear. Our focus is on delivering the infrastructure, performance, and operational accountability our customers are counting on.”

Axe Compute designs, deploys, and operates dedicated AI infrastructure for enterprises building and running production AI workloads. Headquartered in Pittsburgh, the company delivers purpose-built GPU capacity backed by predictable performance, transparent costs, and end-to-end operational accountability.

About Axe Compute Inc.
Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models. Axe Compute provides the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide, supported by enterprise-grade SLAs and operational expertise. Axe Compute is headquartered in Pittsburgh, Pennsylvania. For more information, visit axecompute.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the commencement, timing, deployment and activation of contracted customer projects; deployment and operational capabilities; customer demand; contracted customer projects; capacity roadmap; hardware availability; and the company’s ability to design, deploy, own and operate dedicated AI infrastructure at scale. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Axe Compute undertakes no obligation to update or revise forward-looking statements except as required by applicable law.

Media and Investor Relations Contact

Erin McMahon, CMO and Head of Investor Relations
ir@axecompute.com

Experienced public company legal executive will lead nVent’s global legal, compliance and corporate governance functions

Courtney Nelson Wills

nVent Names Courtney Nelson Wills General Counsel
nVent Names Courtney Nelson Wills General Counsel

LONDON, Sept. 29, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (nVent), a global leader in electrical connection and protection solutions, today announced the appointment of Courtney Nelson Wills as Executive Vice President, General Counsel and Secretary, effective October 12. Wills will report directly to nVent Chair and CEO Beth Wozniak and will lead nVent’s global legal organization, including the compliance, corporate governance and corporate secretary functions. She will be based out of nVent’s management offices in St. Louis Park, MN.

“Courtney is a strategic public company general counsel with decades of legal, business and governance experience across global organizations,” said Beth Wozniak, nVent Chair and CEO. “Her passion for business, technology and people makes her a great fit for nVent, and she will provide strong leadership as we continue to execute our growth strategy.”

Nelson Wills joins nVent with more than 25 years of experience spanning global commercial operations, public-company governance, M&A, intellectual property and regulatory and compliance matters. Most recently, she served as Senior Vice President, General Counsel and Corporate Secretary of MiniMed Group, Inc., a multibillion-dollar spin-off from Medtronic which completed its IPO in early 2026.

“I’m honored to join nVent and excited about the opportunities ahead,” said Courtney Nelson Wills. “nVent is a company with a strong track record, exciting growth strategy and a great culture focused on people and performance. I look forward to working with the leadership team and employees around the world to support the company’s continued success.”

Nelson Wills earned a Juris Doctor from the University of Minnesota Law School and a Bachelor of Science degree in Chemical Engineering from the University of Minnesota.

About nVent 

nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high-performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at www.nVent.com.

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact
Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
Tony.Riter@nVent.com

Media Contact
Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
Kevin.King@nVent.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e2d88a6-bf57-4269-bb58-626c561bcdf7

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.